{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T04:25:24Z","timestamp":1793420724201,"version":"4.5.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Advances"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jacadv.2026.102917","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T19:30:07Z","timestamp":1784748607000},"page":"102917","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cardiovascular and Cerebrovascular Outcomes Risk Reduction Associated With Semaglutide vs Tirzepatide"],"prefix":"10.1016","volume":"5","author":[{"given":"Ahmed Y.","family":"Azzam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammed Amir","family":"Essibayi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranjal","family":"Rai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamza A.","family":"Salim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa S.","family":"Alhasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Anindo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2008-7110","authenticated-orcid":false,"given":"Anas","family":"Hashem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam A.","family":"Dmytriw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Altschul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek S.","family":"Yedavalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabricio","family":"Feltrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumit","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Milburn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7577-1887","authenticated-orcid":false,"given":"Dhairya A.","family":"Lakhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacadv.2026.102917_bib1","doi-asserted-by":"crossref","first-page":"436","DOI":"10.31083\/j.rcm2512436","article-title":"Diabetes mellitus and cardiovascular disease: exploring epidemiology, pathophysiology, and treatment strategies","volume":"25","author":"Siam","year":"2024","journal-title":"Rev Cardiovasc Med"},{"key":"10.1016\/j.jacadv.2026.102917_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2025.108861","article-title":"Cardiovascular therapeutic targets of sodium-glucose co-transporter 2 (SGLT2) inhibitors beyond heart failure","volume":"270","author":"Armillotta","year":"2025","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jacadv.2026.102917_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2025.101740","article-title":"An observational study of cardiovascular outcomes of tirzepatide vs glucagon-like Peptide-1 receptor agonists","volume":"4","author":"Dani","year":"2025","journal-title":"JACC Adv"},{"key":"10.1016\/j.jacadv.2026.102917_bib4","doi-asserted-by":"crossref","first-page":"428","DOI":"10.3390\/jcm14020428","article-title":"The triad of risk: linking MASLD, cardiovascular disease and type 2 diabetes; from pathophysiology to treatment","volume":"14","author":"Michalopoulou","year":"2025","journal-title":"J Clin Med"},{"key":"10.1016\/j.jacadv.2026.102917_bib5","doi-asserted-by":"crossref","first-page":"399","DOI":"10.3390\/ph18030399","article-title":"Semaglutide as a GLP-1 agonist: a breakthrough in obesity treatment","volume":"18","author":"Salvador","year":"2025","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.jacadv.2026.102917_bib6","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1001\/jamainternmed.2024.2525","article-title":"Semaglutide vs tirzepatide for weight loss in adults with overweight or obesity","volume":"184","author":"Rodriguez","year":"2024","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jacadv.2026.102917_bib7","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/653789","article-title":"Impact of diabetes on cardiovascular disease: an update","volume":"2013","author":"Matheus","year":"2013","journal-title":"Int J Hypertens"},{"key":"10.1016\/j.jacadv.2026.102917_bib8","doi-asserted-by":"crossref","first-page":"444","DOI":"10.4239\/wjd.v5.i4.444","article-title":"Type 2 diabetes and cardiovascular disease: have all risk factors the same strength?","volume":"5","author":"Mart\u00edn-Tim\u00f3n","year":"2014","journal-title":"World J Diabetes"},{"key":"10.1016\/j.jacadv.2026.102917_bib9","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.3390\/nu16162781","article-title":"Update on obesity and cardiovascular risk: from pathophysiology to clinical management","volume":"16","author":"Gallo","year":"2024","journal-title":"Nutrients"},{"key":"10.1016\/j.jacadv.2026.102917_bib10","doi-asserted-by":"crossref","first-page":"24","DOI":"10.71079\/ASIDE.IM.03222516","article-title":"TriNetX and real-world evidence: a critical review of its strengths, limitations, and bias considerations in clinical research","volume":"1","author":"Nassar","year":"2025","journal-title":"ASIDE Intern Med"},{"key":"10.1016\/j.jacadv.2026.102917_bib11","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available","volume":"183","author":"Hern\u00e1n","year":"2016","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jacadv.2026.102917_bib12","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jclinepi.2016.04.014","article-title":"Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses","volume":"79","author":"Hern\u00e1n","year":"2016","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jacadv.2026.102917_bib13","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1001\/jama.2022.21383","article-title":"Target trial emulation: a framework for causal inference from observational data","volume":"328","author":"Hern\u00e1n","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.jacadv.2026.102917_bib14","doi-asserted-by":"crossref","first-page":"402","DOI":"10.7326\/ANNALS-24-01871","article-title":"The target trial framework for causal inference from observational data: why and when is it helpful?","volume":"178","author":"Hern\u00e1n","year":"2025","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacadv.2026.102917_bib15","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1681\/ASN.0000000000000152","article-title":"Target trial emulation to improve causal inference from observational data: what, why, and how?","volume":"34","author":"Fu","year":"2023","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jacadv.2026.102917_bib16","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1001\/jama.2025.13350","article-title":"Transparent reporting of observational studies emulating a target trial-the TARGET statement","volume":"334","author":"Cashin","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.jacadv.2026.102917_bib17","article-title":"Transparent reporting of observational studies emulating a target trial: the TARGET statement","volume":"390","author":"Cashin","year":"2025","journal-title":"BMJ (Clinical Research ed)"},{"key":"10.1016\/j.jacadv.2026.102917_bib18","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.ijsu.2014.07.013","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"12","author":"Von Elm","year":"2014","journal-title":"Int J Surg"},{"key":"10.1016\/j.jacadv.2026.102917_bib19","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.4103\/sja.SJA_543_18","article-title":"The STROBE guidelines","volume":"13","author":"Cuschieri","year":"2019","journal-title":"Saudi J Anaesth"},{"key":"10.1016\/j.jacadv.2026.102917_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fcdhc.2023.1293926","article-title":"The benefits of GLP1 receptors in cardiovascular diseases","volume":"4","author":"Ferhatbegovi\u0107","year":"2023","journal-title":"Front Clin Diabetes Healthc"},{"key":"10.1016\/j.jacadv.2026.102917_bib21","doi-asserted-by":"crossref","first-page":"6777","DOI":"10.3390\/ijms26146777","article-title":"Molecular insights into the potential cardiometabolic effects of GLP-1 receptor analogs and DPP-4 inhibitors","volume":"26","author":"Kr\u00f3l","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jacadv.2026.102917_bib22","article-title":"SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline","volume":"373","author":"Li","year":"2021","journal-title":"BMJ (Clinical Research ed)"},{"key":"10.1016\/j.jacadv.2026.102917_bib23","doi-asserted-by":"crossref","first-page":"6678","DOI":"10.3390\/jcm14186678","article-title":"Rethinking the diabetes\u2013cardiovascular disease continuum: toward integrated care","volume":"14","author":"Caturano","year":"2025","journal-title":"J Clin Med"},{"key":"10.1016\/j.jacadv.2026.102917_bib24","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12933-022-01516-6","article-title":"Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management","volume":"21","author":"Ma","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jacadv.2026.102917_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2025.1535134","article-title":"Glucagon-like peptide-1 receptor agonists: a review from a cardiovascular perspective","volume":"12","author":"Turkistani","year":"2025","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jacadv.2026.102917_bib26","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1056\/NEJMoa2416394","article-title":"Tirzepatide as compared with semaglutide for the treatment of obesity","volume":"393","author":"Aronne","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2026.102917_bib27","doi-asserted-by":"crossref","DOI":"10.1093\/ehjopen\/oeaf117","article-title":"Tirzepatide compared with semaglutide and 10-year cardiovascular disease risk reduction in obesity: post-hoc analysis of the SURMOUNT-5 trial","volume":"5","author":"Mamas","year":"2025","journal-title":"Eur Heart J Open"},{"key":"10.1016\/j.jacadv.2026.102917_bib28","doi-asserted-by":"crossref","DOI":"10.15420\/cfr.2024.05","article-title":"Effects of glucagon-like Peptide-1 receptor agonists on cardiac function, exercise capacity and quality of life","volume":"10","author":"Shchendrygina","year":"2024","journal-title":"Card Fail Rev"},{"key":"10.1016\/j.jacadv.2026.102917_bib29","doi-asserted-by":"crossref","DOI":"10.1097\/XCE.0000000000000344","article-title":"Glucagon-like peptide-1 receptor agonists and obesity paradox in heart failure with preserved ejection fraction: a systematic review","volume":"14","author":"Hullon","year":"2025","journal-title":"Cardiovasc Endocrinol Metab"},{"key":"10.1016\/j.jacadv.2026.102917_bib30","article-title":"GLP-1RA may have varying effects on cardiac structure in patients with ASCVD depending on BMI","volume":"15","author":"Xu","year":"2024","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.jacadv.2026.102917_bib31","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3390\/cimb47040285","article-title":"The expanding role of GLP-1 receptor agonists: advancing clinical outcomes in metabolic and mental health","volume":"47","author":"Al Qassab","year":"2025","journal-title":"Curr Issues Mol Biol"},{"key":"10.1016\/j.jacadv.2026.102917_bib32","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.7150\/ijbs.59965","article-title":"GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential","volume":"17","author":"Ma","year":"2021","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.jacadv.2026.102917_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103363","article-title":"The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions","volume":"86","author":"Moiz","year":"2025","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jacadv.2026.102917_bib34","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2026.102917_bib35","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/dom.14553","article-title":"The dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: a post hoc analysis","volume":"24","author":"Wilson","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jacadv.2026.102917_bib36","article-title":"Mechanisms of action and therapeutic applications of GLP-1 and dual GIP\/GLP-1 receptor agonists","volume":"15","author":"Liu","year":"2024","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.jacadv.2026.102917_bib37","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.3390\/biomedicines11071875","article-title":"Novel dual incretin receptor agonists in the spectrum of metabolic diseases with a focus on tirzepatide: real game-changers or great expectations? A narrative review","volume":"11","author":"Liarakos","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.jacadv.2026.102917_bib38","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.3390\/ph18091261","article-title":"Pharmacogenomics of tirzepatide: genomic insights into dual GIP\/GLP-1 agonist response in type 2 diabetes and atherosclerosis","volume":"18","author":"Song","year":"2025","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.jacadv.2026.102917_bib39","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1161\/CIRCULATIONAHA.122.059595","article-title":"GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes","volume":"146","author":"Marx","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2026.102917_bib40","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ahj.2024.08.015","article-title":"Effect of tirzepatide on the progression of coronary atherosclerosis using MDCT: rationale and design of the tirzepatide treatment on coronary atherosclerosis progression: the (T-Plaque) randomized-controlled trial design","volume":"278","author":"Hamidi","year":"2024","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacadv.2026.102917_bib41","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1111\/dom.15272","article-title":"Effect of tirzepatide on blood pressure and lipids: a meta-analysis of randomized controlled trials","volume":"25","author":"Kanbay","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jacadv.2026.102917_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2025.147734","article-title":"The mechanistic role of tirzepatide in atherosclerosis: a review","volume":"329","author":"Al-Kuraishy","year":"2025","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.jacadv.2026.102917_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2024.102489","article-title":"Tirzepatide: a novel cardiovascular protective agent in type 2 diabetes mellitus and obesity","volume":"49","author":"Sardar","year":"2024","journal-title":"Curr Probl Cardiol"},{"key":"10.1016\/j.jacadv.2026.102917_bib44","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1186\/s12933-024-02319-7","article-title":"Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of tirzepatide","volume":"23","author":"Taktaz","year":"2024","journal-title":"Cardiovascular Diabetol"},{"key":"10.1016\/j.jacadv.2026.102917_bib45","doi-asserted-by":"crossref","first-page":"213","DOI":"10.12997\/jla.2023.12.3.213","article-title":"The cardiovascular effect of tirzepatide: a glucagon-like Peptide-1 and glucose-dependent insulinotropic polypeptide dual agonist","volume":"12","author":"Cho","year":"2023","journal-title":"J Lipid Atheroscler"},{"key":"10.1016\/j.jacadv.2026.102917_bib46","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s11883-024-01241-3","article-title":"Targeting inflammatory pathways in atherosclerosis: exploring new opportunities for treatment","volume":"26","author":"d\u2019Aiello","year":"2024","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.jacadv.2026.102917_bib47","doi-asserted-by":"crossref","first-page":"4674","DOI":"10.3390\/jcm13164674","article-title":"Cardiovascular protective properties of GLP-1 receptor agonists: more than just diabetic and weight loss drugs","volume":"13","author":"Le","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.jacadv.2026.102917_bib48","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1485801","article-title":"Atherosclerosis: from lipid-lowering and anti-inflammatory therapies to targeting arterial retention of ApoB-containing lipoproteins","volume":"16","author":"Araujo","year":"2025","journal-title":"Front Immunol"}],"container-title":["JACC: Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X26003388?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X26003388?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T20:22:26Z","timestamp":1785529346000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772963X26003388"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":48,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2772963X26003388"],"URL":"https:\/\/doi.org\/10.1016\/j.jacadv.2026.102917","relation":{},"ISSN":["2772-963X"],"issn-type":[{"value":"2772-963X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular and Cerebrovascular Outcomes Risk Reduction Associated With Semaglutide vs Tirzepatide","name":"articletitle","label":"Article Title"},{"value":"JACC: Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacadv.2026.102917","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"102917"}}